Intesa Sanpaolo reports completion of latest tranche in ongoing share buyback programme

Gian Maria Gros-Pietro Chairman of the Board of Directors of Intesa Sanpaolo Wikipedia
Gian Maria Gros-Pietro Chairman of the Board of Directors of Intesa Sanpaolo - Wikipedia
0Comments

Intesa Sanpaolo announced it has executed purchases of its own shares for annulment as part of its ongoing buyback programme. The bank stated that the share repurchases took place between 18 August and 22 August 2025, in line with a plan first disclosed to the market on 26 May 2025 and launched on 2 June 2025.

According to information provided by Morgan Stanley Europe SE, which was appointed as an independent intermediary for the operation, Intesa Sanpaolo acquired a total of 1,920,253 ordinary shares during this period. This represents approximately 0.01% of the bank’s share capital. The average purchase price was reported at 5.5934 euro per share, amounting to a total value of 10,740,717.17 euro.

The transactions were carried out on the regulated market Euronext Milan managed by Borsa Italiana.

“With reference to the execution of the programme of purchase of own shares for annulment (buyback), which was disclosed to the market on 26 May 2025 and launched on 2 June 2025, Intesa Sanpaolo, pursuant to applicable regulations, communicates that – on the basis of information provided by Morgan Stanley Europe SE, the third-party intermediary appointed to execute the programme in full independence and without any involvement of the Intesa Sanpaolo Group – from 18 August to 22 August 2025 the Bank executed the purchase transactions summarised in the table below on the regulated market Euronext Milan managed by Borsa Italiana.”

From 18 August to 22 August 2025, Intesa Sanpaolo purchased a total of “1,920,253 shares, equal to around 0.01% of its share capital, at an average purchase price of 5.5934 euro per share, for a total amount of 10,740,717.17 euro.”

The buyback forms part of Intesa Sanpaolo’s strategy regarding capital management and shareholder returns.



1 Comments
  • Registrera says:
    Your comment is awaiting moderation. This is a preview; your comment will be visible after it has been approved.
    Can you be more specific about the content of your article? After reading it, I still have some doubts. Hope you can help me. https://accounts.binance.com/tr/register?ref=MST5ZREF
  • Related

    Paul Hudson Chief Executive Officer Sanofi SA

    Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

    Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

    Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

    Volvo announces updated share and vote count after series conversion

    The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

    Paul Hudson Chief Executive Officer Sanofi SA

    Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

    Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

    Trending

    The Weekly Newsletter

    Sign-up for the Weekly Newsletter from EU Business Daily.